i)
Stage-specific expression of mouse BST-1/BP-3 on the early B and T
cell progenitors prior to gene rearrangement of antigen receptor.
Ishihara, K., Y. Kobune, Y. Okuyama, M. Itoh, B.O. Lee, O. Muraoka,
and T. Hirano. Int. Immunol. 8: 1395-1404, 1996.
Human bone marrow stromal cell antigen 1 (BST-1) was identified as a
glycosylphosphatidylinositol anchored ectoenzyme expressed on bone
marrow stromal or synovial cell lines and having the ability to
facilitate pre-B cell line growth. The analysis of the expression of
mouse BST-1/BP-3 on the surface of lymphoid cells in the bone marrow
and thymus revealed that it was very transiently expressed on both B
and T cell progenitors undergoing the gene rearrangement of the
antigen receptor. Among CD45R+CD43+ B cell progenitors in the bone
marrow, BST-1 expression appeared on CD24 (heat stable antigen)+,
CD19+, or CD117 (c-kit)+ population. In the thymus, BST-1 was
expressed on CD4-8-3- (TN) CD90 (Thy-1)+ cells. In TN thymocytes, the
majority of CD25+ cells and CD44lo/- cells expressed BST-1. In
fetuses, BST-1+ cells appeared in the thymus and liver at day 14 and
16 of gestation, respectively. The expression level of BST-1 by fetal
thymus was maximal and more than 60% of thymocytes were positive for
BST-1 at day 15 or 16 and the proportion then gradually decreased
during development. Among day 15 fetal thymocytes, BST-1 was negative
on a CD44+CD25- fraction, very slightly positive on the CD44+CD25+
fraction and strongly positive on the CD44lo/-CD25+ and CD44-CD25-
fractions. These results showed that murine BST-1 is a useful marker
for lymphoid progenitor cells initiating gene rearrangement of their
antigen receptors.
|
|
|